<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02818491</url>
  </required_header>
  <id_info>
    <org_study_id>CER 217/15</org_study_id>
    <nct_id>NCT02818491</nct_id>
  </id_info>
  <brief_title>Dexamethasone as an Adjuvant to Ropivacaine for the Interscalene Brachial Plexus Block</brief_title>
  <official_title>Dexamethasone as an Adjuvant to Ropivacaine for the Interscalene Brachial Plexus Block: a Dose-finding Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Vaudois</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Shoulder surgery is associated with moderate to severe postoperative pain. Interscalene
      brachial plexus block is considered by many as the gold standard for treating postoperative
      pain and consists of injecting local anaesthetics close to the nerves of the brachial plexus
      in the neck. Duration of analgesia is between eight to twelve hours depending on the type of
      administered drugs. Dexamethasone 4 mg is a steroid routinely injected intravenously in
      anaesthesia for the prophylaxis of postoperative nausea and vomiting. Recently, different
      trials have demonstrated that combining 4 to 8 mg of dexamethasone with local anaesthetics
      for a perineural injection may prolong the duration of analgesia up to 24 hours. In a
      meta-analysis including 29 trials and 1695 patients, investigators have recently demonstrated
      through a meta-regression that a dose of 4 mg is sufficient and represents a ceiling dose,
      without neurological complications. The objective of this multicenter randomised controlled
      double-blinded trial is to determine the optimal dose of perineural dexamethasone. For that
      purpose, investigators will include a total of 150 patients divided in 5 groups: local
      anaesthetics with placebo, or with dexamethasone 1, 2, 3 and 4 mg.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of analgesia</measure>
    <time_frame>24hour</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of motor block</measure>
    <time_frame>24hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset time of action of sensory block</measure>
    <time_frame>1hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset time of action of motor block</measure>
    <time_frame>1hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Equivalent morphine consumption in postanesthetic care unit</measure>
    <time_frame>4hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Equivalent morphine consumption on postoperative day 1</measure>
    <time_frame>24hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores at rest in postanesthetic care unit (visual analogue scale, 0-10)</measure>
    <time_frame>4hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores on movement in postanesthetic care unit (visual analogue scale, 0-10)</measure>
    <time_frame>4hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores at rest on postoperative day 1 (visual analogue scale, 0-10)</measure>
    <time_frame>24hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores on movement on postoperative day 1 (visual analogue scale, 0-10)</measure>
    <time_frame>24hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of postoperative nausea and vomiting (PONV)</measure>
    <time_frame>24hour</time_frame>
    <description>Presence of PONV (YES/NO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of pruritus</measure>
    <time_frame>24hour</time_frame>
    <description>Presence of pruritus (YES/NO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction score on postoperative day 1 (visual analogue scale, 0-10)</measure>
    <time_frame>24hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemia in postanesthetic care unit (mmol/l)</measure>
    <time_frame>4hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of infection</measure>
    <time_frame>24hour</time_frame>
    <description>Presence of infection (YES/NO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of infection</measure>
    <time_frame>7 days</time_frame>
    <description>Presence of infection (YES/NO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of paresthesia</measure>
    <time_frame>7 days</time_frame>
    <description>Presence of paresthesia (YES/NO)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of muscle weakness</measure>
    <time_frame>7 days</time_frame>
    <description>Presence of muscle weakness (YES/NO)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive ropivacaine 0.5% 20 mls with normal saline 0.9% 2 mls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dex 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 1 mg in 2 mls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dex 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 2 mg in 2 mls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dex 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 3 mg in 2 mls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dex 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive ropivacaine 0.5% 20 mls with dexamethasone 4 mg in 2 mls</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline 0.9% in 2 mls</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 1 mg</intervention_name>
    <description>Dexamethasone 1 mg in 2 mls</description>
    <arm_group_label>Dex 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 2 mg</intervention_name>
    <description>Dexamethasone 2 mg in 2 mls</description>
    <arm_group_label>Dex 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 3 mg</intervention_name>
    <description>Dexamethasone 3 mg in 2 mls</description>
    <arm_group_label>Dex 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone 4 mg</intervention_name>
    <description>Dexamethasone 4 mg in 2 mls</description>
    <arm_group_label>Dex 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine 0.5%</intervention_name>
    <description>Ropivacaine 0.5% 20 mls</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Dex 1</arm_group_label>
    <arm_group_label>Dex 2</arm_group_label>
    <arm_group_label>Dex 3</arm_group_label>
    <arm_group_label>Dex 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients scheduled for elective shoulder arthroscopy

          -  duration of surgery less than 4 hours

        Exclusion Criteria:

          -  allergy to local anaesthetics

          -  history of neck surgery

          -  history of neck radiotherapy

          -  severe respiratory disease

          -  diabetic patient

          -  chronic pain condition

          -  pregnancy

          -  patient suffering from cancer

          -  patient with addicted disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Albrecht, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthias Matthias, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AZ Groeninge Hospital, Pres. Kennedylaan 4, 8500 Kortrijk, Belgium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthias Desmet, MD</last_name>
    <phone>+32 493 18 77 39</phone>
    <email>matthias.desmet@azgroeninge.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eric Albrecht, MD</last_name>
    <phone>+41 79 556 63 41</phone>
    <email>eric.albrecht@chuv.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AZ Groeninge Hospital</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Desmet</last_name>
      <phone>+32 493 18 77 39</phone>
      <email>matthias.desmet@azgroeninge.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre Hospitalier Universitaire Vaudois</investigator_affiliation>
    <investigator_full_name>Eric Albrecht</investigator_full_name>
    <investigator_title>PD MD, Program director of regional anaesthesia</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

